5.56  0.06 (1.09%)		12-07 16:00
Open: 5.5 High: 5.62 Volume: 11,609		Pre. Close: 5.5 Low: 5.48 Market Cap: 118(M)

Short term
Mid term
Targets	6-month :	6.98	1-year :	8.15
Resists	First :	5.98	Second :	6.98
Pivot price	5.53
Supports	First :	4.69	Second :	3.9
MAs	MA(5) :	5.63	MA(20) :	5.24
	MA(100) :	4.76	MA(250) :	5.2
MACD	MACD :	0.3	Signal :	0.3
%K %D	K(14,3) :	69.4	D(3) :	76.5
RSI	RSI(14): 62.2
52-week	High :	10.3	Low :	2.35

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACHV ] has closed below upper band by 47.3%. Bollinger Bands are 1.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.58 - 5.61	5.61 - 5.64
Low:	5.39 - 5.41	5.41 - 5.44
Close:	5.45 - 5.5	5.5 - 5.54

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Thu, 30 Nov 2023
While institutions invested in Achieve Life Sciences, Inc. (NASDAQ:ACHV) benefited from last week's 11% gain, individual investors stood to gain the most - Simply Wall St

Sat, 11 Nov 2023
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 09 Nov 2023
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update - GlobeNewswire

Thu, 26 Oct 2023
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on ... - Yahoo Finance

Mon, 14 Aug 2023
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update - Yahoo Finance

Tue, 11 Jul 2023
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of ... - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	21 (M)
Held by Insiders	2.095e+007 (%)
Held by Institutions	7.7 (%)
Shares Short	693 (K)
Shares Short P.Month	0 (K)

EPS	-3.349e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-87.8 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	277.69
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-31 (M)

PE Ratio	-0.01
PEG Ratio	-0.3
Price to Book value	0
Price to Sales	0.02
Price to Cash Flow	42.13

Dividend	0
Forward Dividend	686700
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.